Sleep Apnea Device Receives FDA Approval
Randomized trial data support the approval, with sustained improvements in apnea severity observed.
By
Kathryn Wighton
March 19, 2026
Clinical Scorecard: Sleep Apnea Device Receives FDA Approval
At a Glance
Category Detail
Condition Obstructive Sleep Apnea Key Mechanisms Proximal hypoglossal nerve stimulation via six electrodes to access airway-controlling muscles. Target Population Adult patients with moderate to severe obstructive sleep apnea who have failed, do not tolerate, or are ineligible for first-line therapies. Care Setting Clinical settings for patients with obstructive sleep apnea.
Key Highlights
FDA approved the aura6000 System for hypoglossal nerve stimulation. Indicated for patients with apnea-hypopnea index between 15 and 65. 65% of patients met responder criteria at 12 months. Median apnea-hypopnea index decreased from 34.3 to 11.0 events per hour. Device does not require drug-induced sleep endoscopy prior to implantation. Guideline-Based Recommendations
Diagnosis
Assess apnea-hypopnea index to determine eligibility for treatment. Management
Consider hypoglossal nerve stimulation for patients intolerant to or ineligible for CPAP. Monitoring & Follow-up
Evaluate apnea-hypopnea index and oxygen desaturation index at follow-up. Risks
Monitor for potential complications related to device implantation. Patient & Prescribing Data
Adults with moderate to severe obstructive sleep apnea.
Customizable titration options available for therapy delivery.
Clinical Best Practices
Utilize data from the OSPREY trial to inform treatment decisions. Ensure thorough patient selection based on apnea-hypopnea index. References
